Synaptotoxicity in Alzheimer's disease:: The Wnt signaling pathway as a molecular target

被引:60
作者
Inestrosa, Nibaldo C. [1 ]
Varela-Nallar, Lorena [1 ]
Grabowski, Catalina P. [1 ]
Colombres, Marcela [1 ]
机构
[1] Univ Chile, Fac Biol Sci, Biomed Ctr, Santiago, Chile
关键词
Wnt signaling; beta-catenin; GSK-3; beta; neurodegeneration; Alzheimer's disease;
D O I
10.1080/15216540701242490
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Recent evidence supports a role of the Wnt pathway in neurodegenerative disorders such as Alzheimer's disease (AD). A relationship between amyloid-beta-peptide (Ab)-induced neurotoxicity and a decrease in the cytoplasmatic levels of beta-catenin has been proposed. Also, the inhibition of glycogen synthase kinase (GSK-3 beta), a central modulator of the pathway, protects rat hippocampal neurons from A beta-induced damage. Interestingly, during the progression of AD, it has been described that active GSK-3 beta is found in neuronal cell bodies and neurites, co-localizing with preneurofibrillary tangles observed in disease brains. Since A beta oligomers are associated with the post-synaptic region and we have found that the non-canonical Wnt signaling modulates PSD-95 and glutamate receptors, we propose that the synaptic target for Ab oligomers in AD is the postsynaptic region and at the molecular level is the non-canonical Wnt signaling pathway. Altogether, our evidence suggests that a sustained loss of Wnt signaling function may be involved in the A beta-dependent neurodegeneration observed in AD brains and that the activation of this signaling pathway could be of therapeutic interest in AD.
引用
收藏
页码:316 / 321
页数:6
相关论文
共 37 条
[1]
Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses [J].
Almeida, CG ;
Tampellini, D ;
Takahashi, RH ;
Greengard, P ;
Lin, MT ;
Snyder, EM ;
Gouras, GK .
NEUROBIOLOGY OF DISEASE, 2005, 20 (02) :187-198
[2]
Wnt signaling to β-catenin involves two interactive components -: Glycogen synthase kinase-3β inhibition and activation of protein kinase C [J].
Chen, RH ;
Ding, WV ;
McCormick, F .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (23) :17894-17899
[3]
Natural oligomers of the amyloid-protein specifically disrupt cognitive function [J].
Cleary, JP ;
Walsh, DM ;
Hofmeister, JJ ;
Shankar, GM ;
Kuskowski, MA ;
Selkoe, DJ ;
Ashe, KH .
NATURE NEUROSCIENCE, 2005, 8 (01) :79-84
[4]
An overview of the current and novel drugs for Alzheimer's disease with particular reference to anti-cholinesterase compounds [J].
Colombres, M ;
Sagal, JP ;
Inestrosa, NC .
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (25) :3123-3132
[5]
COLOMBRES M, 2006, GLYCOGEN SYNTHASE KI
[6]
Activation of Wnt signaling and behavioral impairments rescues neurodegeneration induced by β-amyloid fibrils [J].
De Ferrari, GV ;
Chacón, MA ;
Barría, MI ;
Garrido, JL ;
Godoy, JA ;
Olivares, G ;
Reyes, AE ;
Alvarez, A ;
Bronfman, M ;
Inestrosa, NC .
MOLECULAR PSYCHIATRY, 2003, 8 (02) :195-208
[7]
Wnt signaling function in Alzheimer's disease [J].
De Ferrari, GV ;
Inestrosa, NC .
BRAIN RESEARCH REVIEWS, 2000, 33 (01) :1-12
[8]
The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from β-amyloid neurotoxicity by acting on Wnt signaling components [J].
Farías, GG ;
Godoy, JA ;
Vázquez, MC ;
Adani, R ;
Meshulam, H ;
Avila, J ;
Amitai, G ;
Inestrosa, NC .
NEUROBIOLOGY OF DISEASE, 2005, 18 (01) :176-183
[9]
M1 muscarinic receptor activation protects neurons from β-amyloid toxicity.: A role for Wnt signaling pathway [J].
Farías, GG ;
Godoy, JA ;
Hernández, F ;
Avila, J ;
Fisher, A ;
Inestrosa, NC .
NEUROBIOLOGY OF DISEASE, 2004, 17 (02) :337-348
[10]
Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists [J].
Fisher, A .
JAPANESE JOURNAL OF PHARMACOLOGY, 2000, 84 (02) :101-112